ArticleBlood advances2021
Transfer to the clinic: refining forward programming of hPSCs to megakaryocytes for platelet production in bioreactors.
Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Laboratory Assessment and Clinical Outlook forAnnals of laboratory medicine · 2026Review
- From Donation to Innovation: New Blood-Derived Products.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
- Collagen nanofiber reinforced alginate hydrogel tube microbioreactors for cell culture.Frontiers in bioengineering and biotechnology · 2026Article
- Culturing Potential: advances in ex vivo cell culture systems for haematopoietic cell-based regenerative therapies.Regenerative therapy · 2025Review
- Production of plateletsHaematologica · 2025Article
- Transfusion biomaterials for hemostasis.Journal of thrombosis and haemostasis : JTH · 2025Review
- Targeting cargo to an unconventional secretory system within megakaryocytes allows the release of transgenic proteins from platelets.Journal of thrombosis and haemostasis : JTH · 2024Article
- Circulating platelets modulate oligodendrocyte progenitor cell differentiation during remyelination.eLife · 2024Article
- Forward programming of hiPSCs towards beta-like cells using Ngn3, Pdx1, and MafA.Scientific reports · 2024Article
- Baffled-flow culture system enables the mass production of megakaryocytes from human embryonic stem cells by enhancing mitochondrial function.Cell proliferation · 2023Article
- Generating hematopoietic cells from human pluripotent stem cells: approaches, progress and challenges.Cell regeneration (London, England) · 2023Review
- Human iPS Cells for Clinical Applications and Cellular Products.Handbook of experimental pharmacology · 2023Article
- Manufacturing with pluripotent stem cells (PSConf 2021): Key issues for future research and development.Cell proliferation · 2022Article
- Basic science research opportunities in thrombosis and hemostasis: Communication from the SSC of the ISTH.Journal of thrombosis and haemostasis : JTH · 2022Article
- [Establishment of a platelet production model by bone marrow cavity transplantation of mouse primary megakaryocytes].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Mapping the biogenesis of forward programmed megakaryocytes from induced pluripotent stem cells.Science advances · 2022Article
- Review
- Conditional CRISPR-mediated deletion of Lyn kinase enhances differentiation and function of iPSC-derived megakaryocytes.Journal of thrombosis and haemostasis : JTH · 2022Article
- The heterogeneity of megakaryocytes and platelets and implications for ex vivo platelet generation.Stem cells translational medicine · 2021Review
- Improving Human Induced Pluripotent Stem Cell-Derived Megakaryocyte Differentiation and Platelet Production.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
Abstract
The production of in vitro-derived platelets has great potential for transfusion medicine. Here, we build on our experience in the forward programming (FoP) of human pluripotent stem cells (hPSCs) to megakaryocytes (MKs) and address several aspects of the complex challenges to bring this technology to the bedside. We first identify clinical-grade hPSC lines that generate MKs efficiently. We design a bespoke media to maximize both production and maturity of MKs and improve platelet output. Crucially, we transition the lentiviral-based FoP of hPSCs to a nonviral inducible system. We also show how small molecules promote a definitive hematopoiesis phenotype during the differentiation process, thereby increasing the quality of the final product. Finally, we generate platelets using a bioreactor designed to reproduce the physical cues that promote platelet production in the bone marrow. We show that these platelets are able to contribute to both thrombus formation in vitro and have a hemostatic effect in thrombocytopenic mice in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.